In case you missed it. @ACRheum #COVIDvaccine guidance v 4.0 for Rheum patients & what's added: 👉3rd dose recommend, timing relative to meds (as before) 👉mRNA booster preferred if initial doses were mRNA 👉mAb as PrEP/Rx for high risk pts https://t.co/R8K8WeZBMt

• https://www.rheumatology.org/Portals/0/Files/COVID-19-Vaccine-Clinical-Guidance…

Abst#0858 Hopkins SLE Cohort 860 pts, 65 w/COVID19, 228 vax'd: 👉COVID19 infx did not increase dz activity, but aPLs were increased (rash decreased likely d/t quarantine and no sun exposure) 👉COVID19 vaccine did not affect dz activity #ACR21 @rheumnow https://t.co/C65qJuMIbk

• Effect of COVID Infection and COVID Vaccination on SLE Activity, Including Anti…

So fitting that @ACRheum President @DrDavidKarp has highlighted the amazing work of @rheum_covid in the #ACR21 Opening Session. In crazy times, it delivered results with unprecedented speed, when our patients needed it most. We will look back in history with thanks. @RheumNow https://t.co/cTnAZP9UDl

Abst 0501 Kakkar & colleagues examined immunogenicity of single dose of SARS-CoV-2 Vaccine in patients with systemic sclerosis - Vaccine is safe - Immunosuppression lowered Ab production but no effect on T cell response #ACR21 @RheumNow https://t.co/NsLrWHh7ZS

#LongCovid management #ACR21 #CDC 🔴Multidisciplinary approach: Holistic management 🟢Arthralgias" NSAIDs 🟢Brain fog: cognitive training 🟢 Anosmia/ dysgeusia: olfactory training 🟢 Fatigue: Exercise 🟢 Anxiety/ Depression/ PTSD: psychotherapy #ACRambassador https://t.co/dB1OHlO0bl

Excellent session on COVID-19 update on therapeutics chaired by @rheum_cat Prof. Luis Ostrosky outlining the therapies at different phases of COVID-19 including antivirals, convalescent plasma, anticoagulation, exercise and long-term endemic phase @RheumNow #ACR21 Session6S424 https://t.co/jso7x1v1oA

Young et al. Impact of COVID-19 on rheumatology training 302 rheumatology trainees from 33 countries surveyed ➡️52% feel burned out🔼from prior ➡️66% felt supported by their program ➡️72% felt positive about being in Rheumatology Abst#0485 #ACR21 @RheumNow @kristenyoung

@kristenyoung @rheum_covid project on impact of COVID-19 on our trainees. Love the graphics by @EBRheum . Negatives are physical health, stress levels, and burnout all ⬆️ . Positives? Trainees did feel supported by programmes. Abstr#0485 #ACR21 @RheumNow https://t.co/kXQ1AUNrgb

My exclusive interview w/the GRA Powerhouse! What are they studying next? 👉impact of COVID policies on Rheum pts 👉pt's perception w/COVID vaccines 👉COVID risk calculator 👉long haulers w/ rheum dz 👉breakthrough infections @rheumnow https://t.co/dVLayNchHT @rheum_covid https://t.co/B1KIjxYt15

• COVID in Rheumatologic Disease Patients: Drs. Sparks, Liew, Yazdany and Dao - Y…

Abs 457 #ACR21 @rheumnow Exciting work by @alhkim and colleagues on SARS-CoV-2 Vaccination in CID patients - Most (90%) developed Ab response but with reduced titers - GC users including some low dose mounted low responses - TNFi reduced in vitro neutralization of delta variant https://t.co/fJxnKmbccc

Abs0266 #acr21 @RheumNow study of impact of pandemic on pts w/SLE (67%), RA (19%), & pSS (8%): 63%reported a flare since the pandemic & 16% had COVID-19. 19% reported no changes to their care.76% reported a change in their mood& emotional health. Was your pts experience similar?

#ClinicalPearl. During Q&A of abst#0457 Kim A, et al plenary at #ACR2021 #ACR21 Dr Kim said with 3rd #COVIDvaccination dose the pts who had little or no response to spike protein DID mount a response. 3rd dose in vulnerable pts works #ACRBest @RheumNow

The good news: Most (around 90%) of people with chronic #inflammatory disease produced antibodies after the #COVID19 vaccine, but it was reduced compared to that of generally healthy people. #ACR21 #Plenary @alhkim https://t.co/KdWtIuuOtA

plenary I. #ACR21 Interesting data with the delta variant from @alhkim https://t.co/oUCOXSc9wA